You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Claims for Patent: 5,212,326

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,212,326

Title:	Sodium hydrogen divalproate oligomer
Abstract:	This invention concerns certain diethyl- or dipropylacetic acid salts of sodium valproate which have physiological properties similar to those of valproic acid or sodium valproate but show highly superior stability characteristics.
Inventor(s):	Meade; Edwin M. (Duncan, CA)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	07/637,828
Patent Claims:	1. An oligomer having a 1:1 molar ratio of sodium valproate and valproic acid of the unit formula, (CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 Na/(CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 H, and containing about 4 to 6 such units. 2. An oral pharmaceutical dosage form for treating the symptoms of epileptic seizures or convulsions, containing as the active principal an oligomer having a 1:1 molar ratio of sodium valproate and valproic acid of the unit formula, (CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 Na/(CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 H, and containing about 4 to 6 such units. 3. An oligomer having a 1:1 molar ratio of sodium valproate and valproic acid of the unit formula, (CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 Na/(CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 H, and containing about 6 such units. 4. An oral pharmaceutical dosage form for treating the symptoms of epileptic seizures or convulsions, containing as the active principal an oligomer having a 1:1 molar ratio of sodium valproate and valproic acid of the unit formula, (CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 Na/(CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 H, and containing about 6 such units. 5. An oligomer having a 1:1 molar ratio of sodium valproate and valproic acid of the unit formula, (CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 Na/(CH.sub.3 CH.sub.2 CH.sub.2).sub.2 CHCO.sub.2 H, and having physical/chemical properties as follows: a. stable, white crystalline powder; b. melting point of 98.degree.-100.degree. C.; and c. an infrared spectrum having strong absorption bands at about 2957, 2872, 2932, 1685, 1555 and 1370 cm.sup.-1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.